Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit
Apellis Pharmaceuticals (Nasdaq: APLS) announced it will present at Stifel’s 2020 Immunology and Inflammation Virtual Summit on October 1, 2020, at 9:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apellis Pharmaceuticals (Nasdaq: APLS) announced it will present at Stifel’s 2020 Immunology and Inflammation Virtual Summit on October 1, 2020, at 9:00 a.m. ET. Cedric Francois, M.D., Ph.D., will participate in a panel discussing “The Evolution of Complement Targeted Therapies.” The event can be accessed live via webcast on the company’s website, with a replay available for 90 days post-event. Apellis specializes in developing therapies for diseases linked to complement cascade activation.
Details
News Market Reaction – APLS
The recorded move for APLS in the trading session of this news was +6.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at Stifel’s 2020 Immunology and Inflammation Virtual Summit on Thursday, October 1, 2020 at 9:00 a.m. ET.
Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a panel discussion titled “The Evolution of Complement Targeted Therapies.” The event will be available live via webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at https://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology. For more information, please visit http://apellis.com.
Investor Contact:
Sam Martin / Maghan Meyers
Argot Partners
sam@argotpartners.com / maghan@argotpartners.com
212.600.1902
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.